相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Combination of L1 methylation and tumor-infiltrating lymphocytes as prognostic marker in advanced gastric cancer
Younghoon Kim et al.
GASTRIC CANCER (2020)
Patient-derived orthotopic xenograft models of sarcoma
Kentaro Igarashi et al.
CANCER LETTERS (2020)
Directing Traffic: How to Effectively Drive T Cells into Tumors
Annabelle J. Anandappa et al.
CANCER DISCOVERY (2020)
Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer-bearing mice and patients
Mingtao Liu et al.
CANCER MEDICINE (2020)
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Youhai Jiang et al.
FRONTIERS IN IMMUNOLOGY (2020)
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial
Kohei Shitara et al.
JAMA ONCOLOGY (2020)
Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice
Kai Zhou et al.
ACTA PHARMACOLOGICA SINICA (2019)
Human gastric cancer modelling using organoids
Therese Seidlitz et al.
GUT (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
Jianming Xu et al.
CLINICAL CANCER RESEARCH (2019)
Myeloid-Derived Suppressor Cells: Major Figures that Shape the Immunosuppressive and Angiogenic Network in Cancer
Eleni-Kyriaki Vetsika et al.
CELLS (2019)
Pembrolizumab in Asia-Pacific patients with advanced head and neck squamous cell carcinoma: Analyses from KEYNOTE-012
Makoto Tahara et al.
CANCER SCIENCE (2018)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
IL-2 and Beyond in Cancer Immunotherapy
John M. Wrangle et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2018)
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
Kohei Shitara et al.
LANCET (2018)
Cancer immunotherapy using checkpoint blockade
Antoni Ribas et al.
SCIENCE (2018)
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy (vol 170, 1109.e1, 2017)
Antoni Ribas et al.
CELL (2018)
Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma
Elizabeth D. Thompson et al.
GUT (2017)
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Yoon-Koo Kang et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy
Marta Luksza et al.
NATURE (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Circulating blood levels of IL-6, IFN-γ, and IL-10 as potential diagnostic biomarkers in gastric cancer: a controlled study
Norma Sanchez-Zauco et al.
BMC CANCER (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
The Immune System in Cancer Prevention, Development and Therapy
Serge M. Candeias et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2016)
The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy
James W. T. Toh et al.
CLINICAL COLORECTAL CANCER (2016)
Targeting the tumor vasculature to enhance T cell activity
Evripidis Lanitis et al.
CURRENT OPINION IN IMMUNOLOGY (2015)
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Matthew M. Gubin et al.
NATURE (2014)
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo
S. Yasuda et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2013)
Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
Philippe Armand et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
History of myeloid-derived suppressor cells
James E. Talmadge et al.
NATURE REVIEWS CANCER (2013)
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Michael Platten et al.
CANCER RESEARCH (2012)
PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines
Weiyi Peng et al.
CANCER RESEARCH (2012)
YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
Shu Tian et al.
CANCER SCIENCE (2011)
Overexpression of Interleukin-1β Induces Gastric Inflammation and Cancer and Mobilizes Myeloid-Derived Suppressor Cells in Mice
Shuiping Tu et al.
CANCER CELL (2008)
Vascular normalization in Rgs5-deficient tumours promotes immune destruction
Juliana Hamzah et al.
NATURE (2008)
分享论文
